Design Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Design Therapeutics is Pratik Shah, benoemd in Aug2023, heeft een ambtstermijn van 3.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.54M, bestaande uit 11.1% salaris en 88.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.21% van de aandelen van het bedrijf, ter waarde $ 1.76M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 5.8 jaar.
Belangrijke informatie
Pratik Shah
Algemeen directeur
US$3.5m
Totale compensatie
| Percentage CEO-salaris | 11.14% |
| Dienstverband CEO | 3.1yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 1.5yrs |
| Gemiddelde ambtstermijn bestuur | 5.8yrs |
Recente managementupdates
Recent updates
A Deeper Dive Into Design Therapeutics
Summary Design Therapeutics reported DT-216P2 efficacy in Friedreich’s ataxia, showing a 6.4-point mFARS improvement—over 4x Skyclarys—despite a small four-patient cohort. Market skepticism persists due to the limited cohort size and lack of near-term data updates, with the next trial design news expected in 4Q26. DSGN holds $222.8 million in cash, no debt, and a runway into 2029, positioning it to advance three clinical programs in competitive rare disease indications. An analysis around Design Therapeutics. Read the full article on Seeking AlphaWe're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
DSGN: Positive Friedreich Ataxia Data Will Support A Higher Future Re Rating
Analysts have nudged their price target on Design Therapeutics higher from $20 to $22, citing updated assumptions for revenue growth, profit margins and future P/E that, in their view, support a somewhat richer fair value. Analyst Commentary Recent Street research on Design Therapeutics has leaned clearly constructive, with several bullish analysts adjusting their models and targets in a way that frames the stock as having improved upside potential relative to prior assumptions.
GeneTAC Biomarker Progress Will Support Long Term Potential In Genetic Neurologic Disease
Catalysts About Design Therapeutics Design Therapeutics focuses on small molecule GeneTAC candidates that aim to increase endogenous frataxin production in Friedreich ataxia. What are the underlying business or industry changes driving this perspective?GeneTAC Biomarker Strategy In Friedreich Ataxia Will Transform Long Term Prospects
Catalysts About Design Therapeutics Design Therapeutics is a biotechnology company developing small molecule GeneTACs such as DT-216 to modulate gene expression in genetic diseases like Friedreich ataxia. What are the underlying business or industry changes driving this perspective?Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Design Therapeutics: Not A Complete Washout Despite Setback
Summary Design Therapeutics' GeneTAC platform offers a novel approach to treating genetic diseases using small molecules, which are more stable and easier to deliver than gene therapies. The lead indication, Friedreich's ataxia, showed promising results with DT-216 but faced setbacks due to injection site thrombophlebitis, leading to the development of DT-216P2. Financially, DSGN has a market cap of $283mn and a cash balance of $254mn, providing a cash runway into 2029 despite delays. The new formulation delays the program by 2–3 years, but the company remains a watchlist candidate for its innovative approach and potential. Read the full article on Seeking AlphaDesign Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Design Therapeutics GAAP EPS of -$0.27 misses by $0.02
Design Therapeutics press release (NASDAQ:DSGN): Q2 GAAP EPS of -$0.27 misses by $0.02. Cash, cash equivalents and marketable securities were $359.4 million as of June 30, 2022.We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$71m |
| Mar 31 2026 | n/a | n/a | -US$70m |
| Dec 31 2025 | US$4m | US$395k | -US$70m |
| Sep 30 2025 | n/a | n/a | -US$67m |
| Jun 30 2025 | n/a | n/a | -US$63m |
| Mar 31 2025 | n/a | n/a | -US$56m |
| Dec 31 2024 | US$790k | US$395k | -US$50m |
| Sep 30 2024 | n/a | n/a | -US$48m |
| Jun 30 2024 | n/a | n/a | -US$51m |
| Mar 31 2024 | n/a | n/a | -US$59m |
| Dec 31 2023 | US$6m | US$361k | -US$67m |
| Sep 30 2023 | n/a | n/a | -US$72m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$69m |
| Dec 31 2022 | US$5m | US$338k | -US$63m |
| Sep 30 2022 | n/a | n/a | -US$57m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | US$585k | US$310k | -US$36m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$19m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$400k | US$250k | -US$8m |
Compensatie versus markt: De totale vergoeding ($USD 3.54M ) Pratik } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.51M ).
Compensatie versus inkomsten: De vergoeding van Pratik is gestegen terwijl het bedrijf verliesgevend is.
CEO
Pratik Shah (56 yo)
Dr. Pratik Shah, Ph D., is an Executive Chairperson at Design Therapeutics, Inc. since December 2017 and serves as its President, Chief Executive Officer and Principal Financial Officer since August 25, 20...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 3.1yrs | US$3.54m | 0.21% $ 1.8m | |
| Chief Operating Officer | 5.7yrs | US$1.89m | 1.31% $ 11.1m | |
| Chief Medical Officer | 1.4yrs | US$2.03m | 0% $ 0 | |
| Co-Founder & Scientific Advisor | no data | geen gegevens | 12.25% $ 103.7m | |
| Chief Accounting Officer | 5yrs | geen gegevens | geen gegevens | |
| Chief Technology Officer | 1.5yrs | geen gegevens | geen gegevens | |
| General Counsel | no data | geen gegevens | geen gegevens | |
| Chief Scientific Officer | 1.5yrs | geen gegevens | geen gegevens | |
| Chief of Manufacturing & Product Development | 1.5yrs | geen gegevens | geen gegevens | |
| Chief Chemist | 1.5yrs | geen gegevens | geen gegevens |
Ervaren management: Het managementteam van DSGN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 8.8yrs | US$3.54m | 0.21% $ 1.8m | |
| Co-Founder & Scientific Advisor | no data | geen gegevens | 12.25% $ 103.7m | |
| Independent Director | 5.8yrs | US$120.71k | 0.092% $ 779.3k | |
| Independent Director | 1yr | US$223.78k | 0% $ 0 | |
| Independent Director | less than a year | geen gegevens | 0% $ 0 | |
| Independent Director | 7.2yrs | US$239.04k | 0.21% $ 1.8m | |
| Lead Independent Director | 6.6yrs | US$136.67k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$109.71k | 0.0021% $ 17.6k |
Ervaren bestuur: De raad van bestuur van DSGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/15 09:33 |
| Aandelenkoers aan het einde van de dag | 2026/09/15 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Design Therapeutics, Inc. wordt gevolgd door 9 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Ioannis Souroutzidis | Cantor Fitzgerald & Co. |
| Adam Vogel | Craig-Hallum Capital Group LLC |
| Madhu Kumar | Goldman Sachs |